Data analytics identify glycated haemoglobin co-markers for type 2 diabetes mellitus diagnosis

Herbert F. Jelinek, Andrew Stranieri, Andrew Yatsko, Sitalakshmi Venkatraman

Research output: Contribution to journalArticle

13 Citations (Scopus)
16 Downloads (Pure)

Abstract

Glycated haemoglobin (HbA1c) is being more commonly used as an alternative test for the identification of type 2 diabetes mellitus (T2DM) or to add to fasting blood glucose level and oral glucose tolerance test results, because it is easily obtained using point-of-care technology and represents long-term blood sugar levels. HbA1c cut-off values of 6.5% or above have been recommended for clinical use based on the presence of diabetic comorbidities from population studies. However, outcomes of large trials with a HbA1c of 6.5% as a cut-off have been inconsistent for a diagnosis of T2DM. This suggests that a HbA1c cut-off of 6.5% as a single marker may not be sensitive enough or be too simple and miss individuals at risk or with already overt, undiagnosed diabetes. In this study, data mining algorithms have been applied on a large clinical dataset to identify an optimal cut-off value for HbA1c and to identify whether additional biomarkers can be used together with HbA1c to enhance diagnostic accuracy of T2DM. T2DM classification accuracy increased if 8-hydroxy-2-deoxyguanosine (8-OhdG), an oxidative stress marker, was included in the algorithm from 78.71% for HbA1c at 6.5% to 86.64%. A similar result was obtained when interleukin-6 (IL-6) was included (accuracy=85.63%) but with a lower optimal HbA1c range between 5.73 and 6.22%. The application of data analytics to medical records from the Diabetes Screening programme demonstrates that data analytics, combined with large clinical datasets can be used to identify clinically appropriate cut-off values and identify novel biomarkers that when included improve the accuracy of T2DM diagnosis even when HbA1c levels are below or equal to the current cut-off of 6.5%.
Original languageEnglish
Pages (from-to)90-97
Number of pages8
JournalComputers in Biology and Medicine
Volume75
DOIs
Publication statusPublished - 01 Aug 2016

Fingerprint

Hemoglobin
Glycosylated Hemoglobin A
Medical problems
Type 2 Diabetes Mellitus
Blood Glucose
Biomarkers
Point-of-Care Systems
Glucose
Data Mining
Blood
Glucose Tolerance Test
Medical Records
Comorbidity
Oxidative stress
Interleukin-6
Fasting
Oxidative Stress
Sugars
Data mining
Screening

Cite this

Jelinek, Herbert F. ; Stranieri, Andrew ; Yatsko, Andrew ; Venkatraman, Sitalakshmi. / Data analytics identify glycated haemoglobin co-markers for type 2 diabetes mellitus diagnosis. In: Computers in Biology and Medicine. 2016 ; Vol. 75. pp. 90-97.
@article{c0832831e63a4493a57663083b373cab,
title = "Data analytics identify glycated haemoglobin co-markers for type 2 diabetes mellitus diagnosis",
abstract = "Glycated haemoglobin (HbA1c) is being more commonly used as an alternative test for the identification of type 2 diabetes mellitus (T2DM) or to add to fasting blood glucose level and oral glucose tolerance test results, because it is easily obtained using point-of-care technology and represents long-term blood sugar levels. HbA1c cut-off values of 6.5{\%} or above have been recommended for clinical use based on the presence of diabetic comorbidities from population studies. However, outcomes of large trials with a HbA1c of 6.5{\%} as a cut-off have been inconsistent for a diagnosis of T2DM. This suggests that a HbA1c cut-off of 6.5{\%} as a single marker may not be sensitive enough or be too simple and miss individuals at risk or with already overt, undiagnosed diabetes. In this study, data mining algorithms have been applied on a large clinical dataset to identify an optimal cut-off value for HbA1c and to identify whether additional biomarkers can be used together with HbA1c to enhance diagnostic accuracy of T2DM. T2DM classification accuracy increased if 8-hydroxy-2-deoxyguanosine (8-OhdG), an oxidative stress marker, was included in the algorithm from 78.71{\%} for HbA1c at 6.5{\%} to 86.64{\%}. A similar result was obtained when interleukin-6 (IL-6) was included (accuracy=85.63{\%}) but with a lower optimal HbA1c range between 5.73 and 6.22{\%}. The application of data analytics to medical records from the Diabetes Screening programme demonstrates that data analytics, combined with large clinical datasets can be used to identify clinically appropriate cut-off values and identify novel biomarkers that when included improve the accuracy of T2DM diagnosis even when HbA1c levels are below or equal to the current cut-off of 6.5{\%}.",
keywords = "Data analytics, Glycated haemoglobin, Type 2 diabetes mellitus",
author = "Jelinek, {Herbert F.} and Andrew Stranieri and Andrew Yatsko and Sitalakshmi Venkatraman",
year = "2016",
month = "8",
day = "1",
doi = "10.1016/j.compbiomed.2016.05.005",
language = "English",
volume = "75",
pages = "90--97",
journal = "Computers in Biology and Medicine",
issn = "0010-4825",
publisher = "Elsevier",

}

Data analytics identify glycated haemoglobin co-markers for type 2 diabetes mellitus diagnosis. / Jelinek, Herbert F.; Stranieri, Andrew; Yatsko, Andrew; Venkatraman, Sitalakshmi.

In: Computers in Biology and Medicine, Vol. 75, 01.08.2016, p. 90-97.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Data analytics identify glycated haemoglobin co-markers for type 2 diabetes mellitus diagnosis

AU - Jelinek, Herbert F.

AU - Stranieri, Andrew

AU - Yatsko, Andrew

AU - Venkatraman, Sitalakshmi

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Glycated haemoglobin (HbA1c) is being more commonly used as an alternative test for the identification of type 2 diabetes mellitus (T2DM) or to add to fasting blood glucose level and oral glucose tolerance test results, because it is easily obtained using point-of-care technology and represents long-term blood sugar levels. HbA1c cut-off values of 6.5% or above have been recommended for clinical use based on the presence of diabetic comorbidities from population studies. However, outcomes of large trials with a HbA1c of 6.5% as a cut-off have been inconsistent for a diagnosis of T2DM. This suggests that a HbA1c cut-off of 6.5% as a single marker may not be sensitive enough or be too simple and miss individuals at risk or with already overt, undiagnosed diabetes. In this study, data mining algorithms have been applied on a large clinical dataset to identify an optimal cut-off value for HbA1c and to identify whether additional biomarkers can be used together with HbA1c to enhance diagnostic accuracy of T2DM. T2DM classification accuracy increased if 8-hydroxy-2-deoxyguanosine (8-OhdG), an oxidative stress marker, was included in the algorithm from 78.71% for HbA1c at 6.5% to 86.64%. A similar result was obtained when interleukin-6 (IL-6) was included (accuracy=85.63%) but with a lower optimal HbA1c range between 5.73 and 6.22%. The application of data analytics to medical records from the Diabetes Screening programme demonstrates that data analytics, combined with large clinical datasets can be used to identify clinically appropriate cut-off values and identify novel biomarkers that when included improve the accuracy of T2DM diagnosis even when HbA1c levels are below or equal to the current cut-off of 6.5%.

AB - Glycated haemoglobin (HbA1c) is being more commonly used as an alternative test for the identification of type 2 diabetes mellitus (T2DM) or to add to fasting blood glucose level and oral glucose tolerance test results, because it is easily obtained using point-of-care technology and represents long-term blood sugar levels. HbA1c cut-off values of 6.5% or above have been recommended for clinical use based on the presence of diabetic comorbidities from population studies. However, outcomes of large trials with a HbA1c of 6.5% as a cut-off have been inconsistent for a diagnosis of T2DM. This suggests that a HbA1c cut-off of 6.5% as a single marker may not be sensitive enough or be too simple and miss individuals at risk or with already overt, undiagnosed diabetes. In this study, data mining algorithms have been applied on a large clinical dataset to identify an optimal cut-off value for HbA1c and to identify whether additional biomarkers can be used together with HbA1c to enhance diagnostic accuracy of T2DM. T2DM classification accuracy increased if 8-hydroxy-2-deoxyguanosine (8-OhdG), an oxidative stress marker, was included in the algorithm from 78.71% for HbA1c at 6.5% to 86.64%. A similar result was obtained when interleukin-6 (IL-6) was included (accuracy=85.63%) but with a lower optimal HbA1c range between 5.73 and 6.22%. The application of data analytics to medical records from the Diabetes Screening programme demonstrates that data analytics, combined with large clinical datasets can be used to identify clinically appropriate cut-off values and identify novel biomarkers that when included improve the accuracy of T2DM diagnosis even when HbA1c levels are below or equal to the current cut-off of 6.5%.

KW - Data analytics

KW - Glycated haemoglobin

KW - Type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=84973129920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973129920&partnerID=8YFLogxK

U2 - 10.1016/j.compbiomed.2016.05.005

DO - 10.1016/j.compbiomed.2016.05.005

M3 - Article

C2 - 27268735

AN - SCOPUS:84973129920

VL - 75

SP - 90

EP - 97

JO - Computers in Biology and Medicine

JF - Computers in Biology and Medicine

SN - 0010-4825

ER -